.04 mg/dL), P= 0.57]. The mean TSB 48 hours after phototherapy P= 0.02] and the mean duration of phototherapy 
INTRODUCTION
M o s t n e w b o r n s e x p e r i e n c e b e n i g n hyperbilirubinemia. Severe elevation of serum bilirubin levels can result in brain damage, known as kernicterus. [1] [2] [3] [4] [5] It is important to promptly initiate appropriate therapy. The intensity and invasiveness of therapy is determined by many factors such as gestational age, relative health of the neonate, the current level of total bilirubin and the etiology of jaundice. In the neonates, hyperbilirubinemia is usually due to a combination of an increased bilirubin load and decreased bilirubin elimination. [1] [2] [3] [4] [5] Phototherapy and exchange transfusion are two main interventions that are used to decrease total serum bilirubin (TSB). [2, 3] Pharmacologic agents used in the management of hyperbilirubinemia can accelerate bilirubin clearance via the normal metabolic pathways, inhibit the enterohepatic circulation of bilirubin or interfere with bilirubin formation by either blocking the degradation of heme or inhibiting hemolysis. [2, 3, 6] Clofibrate as a hypolipidemic drug is a glucuronosyltransferase inducer which a c c e l e r a t e s b i l i r u b i n e l i m i n a t i o n . [ 7 , 8 ] Hyperbilirubinemia is a common problem in Iranian newborns and constitutes approximately one third of admissions to our neonatal ward. The efÞ cacy of cloÞ brate has been shown in term neonates in several studies. [9] [10] [11] [12] Little is known about the usefulness of this drug in pre-term infants. We hypothesized that near-term infants are not very different from term neonates. So we conducted this study to assess the efÞ cacy and safety of cloÞ brate in the treatment of non-hemolytic jaundice in late pre-term infants.
MATERIALS AND METHODS
This study was a prospective randomized clinical trial conducted in the period from January to December 2008 in the neonatal ward of Tabriz Children Hospital, which is a major teaching and referral center in northwest Iran. Ethical committee of the institute approved the study protocol. Our hospital does not have nursery, and neonates that need readmission after discharge from birth hospitalization would be referred to this hospital. Criteria for enrollment in this study included healthy late pre-term newborns (gestational age, 34-37 weeks) with non-hemolytic jaundice and neonates that did not need urgent exchange transfusion. It is routine to use 2004 AAP hyperbilirubinemia guidelines, [1] for management of admitted newborn infants in our neonatology department.
Neonates with major congenital anomalies; hemolytic disorders; glucose-6-phosphate dehydrogenase deÞ ciency (G6PD) that was diagnosed by qualitative, visual, colorimetric test; sepsis or signiÞ cant accompanying illness requiring NICU admission were excluded. Healthy late pre-term infants admitted for nonhemolytic jaundice were eligible for the trial. Sixty-eight neonates were enrolled in this study. They were randomized into study and control groups by a random-number table sequence after informed parental consents were obtained. The allocation notes were kept in opaque sequentially numbered sealed envelops. Study group received phototherapy and cloÞ brate (n= 35), and control group received phototherapy and placebo (n= 33). Based on the numerical order of sealed envelopes cloÞ brate or placebo was administered to patients by a nurse who was not involved in the care of the infant.
A single dose of clofibrate 100 mg/kg was administered orally to infants in the study group within 12 hours of admission. Phototherapy was started immediately on admission for all studied patients until total serum bilirubin decreased to a safe level depending on the infant's gestation and postnatal age. Each phototherapy unit contained 8 special blue fluorescent tubes labeled TL 52/20w (Philips, Eindhoven, the Netherlands) adjusted at a 20-cm distance above the infant.
Lamps of phototherapy units were changed regularly after 1500 hours of usage. Total and direct serum bilirubin levels were measured 12, 24, 48 hours after admission and then daily until phototherapy was discontinued. TSB measurement was performed on the basis of spectrophotometric principles by using Bilimeter 3, Pfaff Medical GmbH, Germany; and direct bilirubin measurement, by using Autoanalyser Random Access (Selectra E, Vital ScientiÞ c, Netherlands), respectively. The equipments were standardized periodically.
Laboratory tests, including complete blood count, total and direct serum bilirubin, reticulocyte count; and direct Coombs agglutination test, maternal and neonatal blood group, glucose-6-phosphate dehydrogenase determination and peripheral blood smear were performed for all jaundiced infants in both groups. Our criterion for discharge was TSB less than 50% of exchange level, which was ordered by a physician who did not know the infant's group allocation. Duration of phototherapy was recorded by a nurse who was not involved in drug administration.
All infants were examined 48 hours and 1 week after discharge, with a careful physical examination for side effects of treatment, including vomiting, loose stools; and laboratory tests including complete blood count, total serum bilirubin, blood urea nitrogen (BUN) and creatinine were carried out for detection of leucopenia, rebound hyperbilirubinemia and renal failure 1 week after discharge.
All data were analyzed using statistical package of social sciences (SPSS) software for windows version 14. Statistical analysis of data was performed by chi-square and independent sample t test, and P values less than .05 were considered signiÞ cant.
RESULTS
During the study period, the main cause of admission in 144 (32%) neonates of the 446 admitted neonates was hyperbilirubinemia. Seventy neonates fulÞ lled inclusion criteria. Two patients were excluded from the study because of subsequent positive blood culture and refusal by parents for blood sampling. Remaining 68 newborn infants were assigned randomly to the two groups. Of the 68 neonates enrolled in this study, 33 patients in the control group received phototherapy and placebo, while 35 neonates in the study group received phototherapy and clofibrate. There was no signiÞ cant difference in gender, weight, age at admission and cesarean section rate between the two groups [ Table 1 ]. Sixty-Þ ve percent of neonates were first offspring. Ninety-seven percent (66 newborns) of the studied newborns were exclusively breast-fed. Table 2 . None of the patients in the present study required exchange transfusion.
None of the babies receiving clofibrate developed vomiting or diarrhea. We noted only one case of rebound hyperbilirubinemia, which was from the control group, during the followup of neonates. White blood cell count, BUN and creatinine levels were normal 1 week after discharge [ Table 2 ].
DISCUSSION
Despite an understanding of the enzymatic pathways leading to bilirubin production and degradation, very few pharmacologic interventions are utilized and the mainstay of treatment remains phototherapy. In our study, the duration of phototherapy and hospitalization was shorter in late pre-term infants that were treated with clofibrate in addition to phototherapy in comparison with those treated with placebo in addition to phototherapy. No important side effect was determined during the short-term follow-up of patients. CloÞ brate has been used for many years in adults. It is an activator of peroxisome proliferator-activated receptors (PPARs), which decrease serum cholesterol and triglyceride levels. [7] Liver fatty acid-binding protein expression is known to be regulated by PPAR agonists, such as cloÞ brate. In the study by Wang, the up-regulation of liver fatty acid-binding protein was associated with a signiÞ cant decrease in serum bilirubin and alanine aminotransferase by reduction of hepatic oxidative stress and improvement of hepatic function in bile duct-ligated rats. [8] The results of our study are comparable with those of reported trials in term infants [9] [10] [11] [12] and a few studies in pre-term infants. [13, 14] One study showed the usefulness of clofibrate in neonates with G6PD deficiency. [15] In a double-blind controlled study of infants without ABO incompatibility, 47 infants treated with a single dose of clofibrate demonstrated signiÞ cantly lower bilirubin levels after 16 hours of treatment compared to 46 controls given corn oil alone. [9] An interval of 24-48 hours for achieving bilirubin reduction was observed in studies on efficacy of clofibrate in the treatment of hyperbilirubinemia in premature neonates. [13, 14] In our study, serum bilirubin was found signiÞ cantly decreased in the cloÞ brate group after 48 hours. [7, 11, 16] We did not Þ nd gastrointestinal and renal side effects on administration of cloÞ brate in the studied neonates during hospitalization and until 1 week after discharge. The limitation of this study was the small number of patients studied and a short term of their follow-up. Because of non-availability of new pharmacologic medications such as metalloporphyrins for management of hyperbilirubinemia in developing countries, addition of cloÞ brate to phototherapy would be Þ nancially beneÞ cial as it would reduce costs of treatment and duration of hospitalization. The long-term safety of cloÞ brate is debated, and more studies with larger number of patients and longer period follow-up are needed before recommending widespread use of this drug as adjunctive therapy for neonatal hyperbilirubinemia.
Hence there is need for systematic review of the efficacy of clofibrate in neonatal hyperbilirubinemia, as well as its side effects.
